| NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | RECRUITING | PHASE1 | 2024-03-28 | 2042-09-30 | 2027-09-30 |
| NCT06241456 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | RECRUITING | PHASE1 | 2024-01-05 | 2044-05-01 | 2029-05-01 |
| NCT05950334 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | COMPLETED | PHASE1 | 2023-11-16 | 2025-06-30 | 2025-06-06 |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | WITHDRAWN | PHASE1 | 2022-12 | 2039-05 | 2026-05 |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | TERMINATED | PHASE1 | 2022-05-31 | 2023-08-11 | 2023-08-11 |
| NCT05182073 | FT576 in Subjects With Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-11-10 | 2040-02 | 2024-09 |
| NCT05069935 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | TERMINATED | PHASE1 | 2021-10-15 | 2023-08-11 | 2023-08-11 |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-07-12 | 2039-09-30 | 2024-09-30 |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | TERMINATED | PHASE1 | 2020-10-17 | 2023-08-08 | 2023-07-13 |
| NCT04551885 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | TERMINATED | PHASE1 | 2020-09-07 | 2023-08-11 | 2023-08-11 |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | TERMINATED | PHASE1 | 2020-03-19 | 2023-09-27 | 2023-09-27 |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | TERMINATED | PHASE1 | 2019-10-04 | 2023-10-23 | 2023-10-23 |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2019-02-15 | 2022-11-15 | 2022-11-15 |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 | 2018-01-18 | 2020-12-15 | 2020-05-29 |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | COMPLETED | PHASE1, PHASE2 | 2016-12-20 | 2021-11-05 | 2020-12-04 |
| NCT02354443 | A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders | TERMINATED | PHASE1 | 2015-06 | 2017-02 | 2016-12 |
| NCT02354417 | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies | TERMINATED | PHASE1 | 2014-12 | 2017-02 | 2016-12 |
| NCT01627314 | The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. | TERMINATED | PHASE2 | 2012-07 | 2017-05 | 2016-03 |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | COMPLETED | PHASE1 | 2012-01 | 2013-11 | 2013-10 |
| NCT00890500 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | COMPLETED | PHASE1 | 2011-01 | 2013-10 | 2013-05 |